Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large-cell lymphoma (ALCL): A Children’s Oncology Group phase 1 consortium study (ADVL1212)

PURPOSE: This phase 1 study aimed to determine the safety, tolerability and recommended phase 2 dose (RP2D) of crizotinib in combination with cytotoxic chemotherapy for children with refractory solid tumors and ALCL. METHODS: Pediatric patients with treatment refractory solid tumors or ALCL were eli...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Chemother Pharmacol
Main Authors: Greengard, Emily, Mosse, Yael P, Liu, Xiaowei, Minard, Charles G., Reid, Joel M., Voss, Stephan, Wilner, Keith, Fox, Elizabeth, Balis, Frank, Blaney, Susan M., Adamson, Peter C, Weigel, Brenda J
Format: Artigo
Language:Inglês
Published: 2020
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7757912/
https://ncbi.nlm.nih.gov/pubmed/33095287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04171-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items